AATD Drug Pipeline: Z-AAT, mRNA & Gene Therapy — PatSnap Eureka
Alpha-1 Antitrypsin Deficiency: Z-AAT Polymer Inhibitors, mRNA & Gene Therapy Pipeline
From RNAi knockdown and CRISPR base editing to small-molecule pharmacological chaperones and AAV gene therapy — the AATD pipeline is among the most modality-diverse in rare genetic disease. Explore the patent signals shaping this landscape with PatSnap Eureka.
Two Independent Pathological Axes Drive AATD Complexity
Alpha-1 antitrypsin deficiency (AATD) is an autosomal recessive genetic disorder caused by mutations in the SERPINA1 gene. The Z allele (Glu342Lys; E342K substitution) is the predominant disease-causing variant, responsible for misfolding and polymerization of AAT protein within hepatocytes. This creates a dual pathological burden: a gain-of-function hepatotoxicity from intracellular polymer accumulation, and a loss-of-function pulmonary phenotype from insufficient circulating AAT to neutralize neutrophil elastase.
The liver disease axis involves intracellular accumulation of misfolded Z-AAT polymers within hepatocytes, driving chronic hepatitis, cirrhosis, fibrosis, cholestasis, and increased hepatocellular carcinoma risk. This is the primary target for knockdown and gene-correction strategies. The lung disease axis involves insufficiency of circulating functional AAT leading to uncontrolled neutrophil elastase activity and progressive alveolar destruction, driving COPD and emphysema — the primary target for augmentation, elastase inhibition, and gene replacement strategies.
PatSnap's life sciences intelligence platform identifies that no single modality currently addresses both axes simultaneously — a key unmet need explicitly stated in Beam Therapeutics patent filings. Arrowhead Pharmaceuticals specifically frames the Z-AAT protein (both soluble and insoluble fractions) in PiZZ genotype subjects as the direct therapeutic target for RNAi agents, distinguishing soluble from polymer-incorporated Z-AAT as dual contributors to liver pathology. The S allele (Glu264Val) is noted as a milder variant with distinct clinical implications.
Vertex Pharmaceuticals has filed methods for measuring circulating polymeric AAT as a biomarker of liver disease severity and as a pharmacodynamic endpoint for AAT modulators — signaling emerging interest in polymer burden as a translatable, quantifiable clinical endpoint. According to Orphanet, AATD remains a significant rare disease with substantial unmet need, particularly for liver disease where no approved treatments currently exist.
Seven Distinct Approaches to AATD — From Gene Editing to Protein Replacement
The AATD pipeline spans nucleic acid medicines, genomic correction, small molecules, and biological augmentation — each addressing different aspects of the liver and lung disease axes.
RNAi / siRNA — Liver-Targeted Z-AAT Knockdown
The most heavily represented modality in the dataset. Arrowhead Pharmaceuticals leads with GalNAc-conjugated siRNAs targeting hepatic SERPINA1 mRNA via RISC-mediated cleavage, reducing intracellular polymer burden. Dicerna Pharmaceuticals (now Novo Nordisk) holds an extensive Dicer-substrate siRNA (DsiRNA) patent family spanning 2015–2023. Portfolio spans jurisdictions including WO, AU, CA, TW, CN, JP, IL, MX, CO.
Arrowhead · Dicerna/Novo Nordisk · PiZZ genotype targetCRISPR / Base Editing — Correcting the Z Allele at DNA Level
Intellia Therapeutics holds broad CRISPR/Cas9 patents covering both Z-allele knockout and functional AAT knock-in across multiple jurisdictions (IL, CA, AU, IN, EP, NZ) through 2025. Beam Therapeutics uses ABE8 adenosine base editing to correct the G→A Z-mutation at codon 342 with high on-target efficiency and without double-strand breaks — most recent filing December 2024. CRISPR Therapeutics holds a 2017 PCT filing on ex vivo and in vivo SERPINA1 editing.
Intellia · Beam Therapeutics · CRISPR Therapeutics · ABE8ASO & RNA Editing — Transcript-Level Z-Mutation Correction
Ionis Pharmaceuticals (formerly ISIS) filed early ASOs targeting SERPINA1 mRNA. Wave Life Sciences discloses chirally controlled oligonucleotides editing adenosine residues in SERPINA1 transcripts to restore wild-type AAT coding sequence without genomic DNA modification. Korro Bio applies ADAR-mediated A-to-I editing of the Z-mutation transcript. The 2025–2026 filing dates for Wave and Narayanan entries are the most recent in the dataset.
Wave Life Sciences · Korro Bio · Ionis · ADAR editingPharmacological Chaperones — Preventing Z-AAT Polymerization
Vertex Pharmaceuticals holds the largest small-molecule portfolio in the dataset — bicyclic and fused heterocyclic scaffold modulators filed through 2023 (IL, US). GT Gain Therapeutics discloses substituted azole pharmacological chaperones stabilizing native AAT conformation to allow hepatocyte secretion of monomeric protein. UCL Business Ltd and Amicus Therapeutics hold additional compound patents targeting AAT stabilization for both lung and liver indications.
Vertex · GT Gain Therapeutics · UCL Business · AmicusNeutrophil Elastase Inhibitors — Pharmacological NE Substitution
Alvelestat (Mereo BioPharma 4) achieves 72.6% NE activity suppression at clinical Cmax versus 56.7% for AAT augmentation therapy — a comparative pharmacodynamic signal from the EP filing consistent with human PK/PD data. PH Pharma Co. holds multi-jurisdictional patents on a DHPM-based NE inhibitor at doses of 1–40 mg once daily. UAB Research Foundation's 2025 WO filing explicitly claims the combination of alvelestat plus AAT augmentation as a novel treatment method.
Mereo BioPharma 4 · PH Pharma · UAB Research Foundation · AlvelestatProtein Augmentation & AAV Gene Therapy — Restoring Functional AAT
Cornell University has patented an AAV vector encoding an oxidation-resistant AAT with substitutions at Met358 and/or Met351, maintaining elastase-inhibitory activity in the oxidizing pulmonary microenvironment — addressing a recognized limitation of wild-type AAT augmentation. Kamada Ltd has filed on highly fucosylated recombinant human AAT with enhanced immunomodulatory activity. Talecris Biotherapeutics covers subcutaneous plasma-derived AAT; Baxter International discloses nebulized and dry-powder inhaled AAT formulations.
Cornell University · Kamada · Talecris · Baxter · Oxidation-resistant AATKey Quantitative Signals from the AATD Patent Dataset
Visualising patent activity timelines, pharmacodynamic comparisons, and modality-level IP concentration from PatSnap Eureka analysis.
NE Inhibition: Alvelestat vs. AAT Augmentation Therapy
Alvelestat achieves 72.6% neutrophil elastase suppression at clinical Cmax versus 56.7% for standard AAT augmentation — from Mereo BioPharma 4 EP patent filing.
Patent Filing Activity Timeline — Key AATD Assignees
Arrowhead Pharmaceuticals shows sustained multi-jurisdictional filings from 2019–2025; Wave Life Sciences and Beam Therapeutics represent the most recently active programs (2022–2024).
Key Players and Their AATD Patent Strategies
This dataset is overwhelmingly patent-driven. Activity is concentrated among commercial biotechnology and pharmaceutical organizations — academic IP is largely legacy pre-2015.
| Assignee | Primary Modality | Jurisdictions | Filing Window | Development Signal |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals | RNAi / siRNA | WO, AU, CA, TW, CN, JP, IL, MX, CO | 2019–2025 | IND-enabling / Phase 1–2 signals |
| Intellia Therapeutics | CRISPR / Cas9 | IL, CA, AU, IN, EP, NZ | 2019–2025 | Two distinct programs: knockout + knock-in |
| Beam Therapeutics | Base Editing (ABE8) | WO, AU, US, CA, JP | 2020–2024 | Most recent base-editing entry (Dec 2024) |
| Vertex Pharmaceuticals | Small Molecules | IL, US, WO | 2021–2023 | Most advanced small-molecule portfolio breadth |
| Dicerna / Novo Nordisk | DsiRNA | WO, US, CA, AU, EP | 2015–2023 | Portfolio maturation — active and inactive patents |
| Wave Life Sciences | RNA Editing (ASO) | WO, CA, AU, US, IN | 2022–2025 | Most recently filed program cluster in dataset |
| Mereo BioPharma 4 | NE Inhibitor | US, EP, NZ, JP | 2021–2023 | Human PK/PD data signals (72.6% NE suppression) |
| Korro Bio | ADAR RNA Editing | WO, CA | 2021 | Endogenous enzyme-leveraging approach |
| Cornell University | AAV Gene Therapy | WO | 2018 | Oxidation-resistant AAT — preclinical |
Track AATD Competitor IP in Real Time
PatSnap Eureka monitors patent filings across all AATD assignees and alerts you to new activity.
Four Critical Strategic Implications for AATD Drug Development
Derived from patent signal analysis across the AATD landscape. These insights reflect innovation patterns visible in the dataset — not regulatory or clinical guidance.
RNAi and Base Editing Lead Commercial IP Activity
Arrowhead's multi-jurisdictional RNAi portfolio (active through 2025) and Beam's updated base-editing filing (December 2024) signal that IP protection of these platforms is being actively extended, consistent with clinical-stage or near-commercial programs. Competitors entering these spaces face dense IP landscapes. Review PatSnap's IP analytics tools for landscape mapping.
Z-AAT Polymer: Dual Role as Target and Biomarker
Vertex Pharmaceuticals' polymer measurement patents create a parallel IP moat in companion diagnostics — potentially gating competitor access to validated clinical endpoints needed for drug approval studies in AATD. The polymeric AAT species is simultaneously a pathogenic entity and a quantifiable pharmacodynamic endpoint linking polymer inhibition to measurable clinical benefit.
Convergent Strategies Emerging Across Modalities
Retrieved results signal several combination and convergent strategy directions that may define the next generation of AATD therapeutics. The UAB Research Foundation's 2025 WO filing explicitly claims the combination of alvelestat plus AAT augmentation therapy as a novel treatment method — consistent with a synergistic rationale of NE blockade via two mechanisms simultaneously. This filing references NIH grant support (TR002450), suggesting investigator-initiated clinical or late preclinical investigation.
Beam Therapeutics' filings explicitly identify the conceptual limitation of each single modality: knockdown addresses liver toxicity but not lung; augmentation addresses lung but not liver. This signals that RNAi knockdown of Z-AAT combined with functional AAT gene delivery may emerge as clinically necessary — a high-value, underpatented combination space. According to the European Medicines Agency, combination approaches in rare genetic disease are increasingly considered in regulatory frameworks.
Cornell's Met358/Met351 substituted AAT represents a next-generation gene therapy direction — addressing the fundamental oxidative inactivation problem of AAT in the lung microenvironment. Kamada's 2025 patent on highly fucosylated recombinant AAT with enhanced immunomodulatory activity signals convergence between AAT replacement and immunotherapy, targeting non-canonical AAT functions beyond NE inhibition. For deeper analysis of life sciences IP strategy, PatSnap's life sciences solutions provide modality-level landscape mapping.
Most notably, Ageronix SA has filed on AAT protein and AAT-encoding nucleic acids for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) — a highly novel extrapolation of AATD biology into neurology that signals emerging exploration of AAT's broad immunomodulatory functions beyond the canonical AATD indication. The ClinicalTrials.gov registry tracks ongoing AATD combination studies that complement these patent signals.
Alpha-1 Antitrypsin Deficiency Drug Pipeline — Key Questions Answered
AATD is an autosomal recessive genetic disorder caused by mutations in the SERPINA1 gene, most critically the Z allele (E342K substitution), which causes AAT protein to misfold and polymerize within hepatocytes, driving liver disease while simultaneously depriving the lung of the serine protease inhibitor needed to neutralize neutrophil elastase, leading to emphysema and COPD.
The therapeutic landscape spans RNAi-mediated Z-AAT knockdown, CRISPR/base editing genomic correction, small-molecule pharmacological chaperones, antisense oligonucleotide (ASO)-mediated RNA editing, AAV-based gene therapy, neutrophil elastase inhibitors, and protein augmentation strategies.
Arrowhead Pharmaceuticals is the most prolific assignee with filings spanning multiple jurisdictions from 2019–2025, focused on RNAi agents. Other key players include Intellia Therapeutics (CRISPR/Cas9), Beam Therapeutics (adenosine base editing), Vertex Pharmaceuticals (small-molecule modulators), and Dicerna Pharmaceuticals/Novo Nordisk (DsiRNA).
Vertex Pharmaceuticals' patent on measuring circulating polymeric AAT highlights this molecular species not only as a pathogenic entity but as a quantifiable disease-monitoring and drug-efficacy endpoint — an important translational signal linking polymer inhibition directly to measurable clinical benefit.
Alvelestat is a neutrophil elastase (NE) inhibitor developed by Mereo BioPharma 4. Dosing data in filed patents suggests 72.6% NE activity suppression at achieved Cmax, compared to 56.7% for AAT augmentation therapy — a comparative pharmacodynamic claim suggesting human PK/PD data. It approaches AATD lung disease through pharmacological substitution for the lost NE-inhibitory function of AAT.
No single modality addresses both the liver and lung disease axes of AATD. Beam Therapeutics filings explicitly articulate this unmet need: knockdown addresses liver toxicity but not lung; augmentation addresses lung but not liver. Combination strategies — particularly RNAi knockdown of Z-AAT plus functional AAT gene delivery or augmentation — represent a high-value, underpatented space with potential first-mover advantage.
Still have questions about the AATD pipeline? Let PatSnap Eureka answer them with live patent data.
Ask Eureka About AATD PatentsAccelerate Your AATD Drug Discovery and IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to navigate complex rare disease patent landscapes, identify white spaces, and monitor competitor pipelines in real time.
References
- Substituted azoles their use in the treatment of diseases associated with alpha-1-antitrypsin (A1AT) deficiency — GT Gain Therapeutics SA, 2024, WO [Patent]
- Oxidation-resistant AAT gene therapy — Cornell University, 2018, WO [Patent]
- Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) — Arrowhead Pharmaceuticals, Inc., 2020, WO [Patent]
- Compositions and methods for treating alpha-1 antitrypsin deficiency — Beam Therapeutics Inc., 2020, WO [Patent]
- Methods for the reduction of Z-AAT protein levels — Arrowhead Pharmaceuticals, Inc., 2022, CA [Patent]
- Methods of monitoring alpha-1 antitrypsin (AAT) deficiency by measuring polymerised AAT — Vertex Pharmaceuticals, 2022 [Patent]
- Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency — Mereo BioPharma 4 Limited, 2023, US [Patent]
- Alvelestat and alpha-1 antitrypsin for treating respiratory disorders — UAB Research Foundation, 2025, WO [Patent]
- Methods and compositions for the ADAR-mediated editing of SERPINA1 — Korro Bio, Inc., 2021, WO [Patent]
- Methods and compositions for treating alpha-1 antitrypsin deficiency — Beam Therapeutics Inc., 2024, WO [Patent]
- Alpha-1 Antitrypsin Deficiency — NIH / PubMed Central [Literature]
- Alpha-1 Antitrypsin Deficiency — Orphanet Rare Disease Database
- European Medicines Agency — Rare Disease Regulatory Framework
- ClinicalTrials.gov — AATD Clinical Studies Registry
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.